Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Targeting the Erbb family of receptor tyrosine kinases, specifically ERBB1 (EGFR) and ERBB2, has led to successful cancer therapies. However, many patients will progress on these therapies. As we learn more about this pivotal receptor family, can we devise better methods of targeting it?
Chemoprevention of lung carcinogenesis is one potential approach to control the epidemic of lung cancer caused by cigarette smoking. How should we go about this and is using mixtures of chemopreventive agents a useful path to pursue?
New technologies have led to an explosive increase in the number of biomarkers thought to be associated with prognosis and treatment outcome in colorectal cancer. How effective are the biomarkers already in the public domain?
Ever since its discovery, apoptosis has been inextricably linked with cancer. This Timeline article seeks to provide insights into the key discoveries in the field and therapeutic applications based on apoptotic strategies.
Cancer prevention is a global priority, but history indicates that the journey towards achieving this goal is fraught with difficulties. What can we learn from the past that is applicable to the reality of successful cancer prevention?
Cancer in wildlife seems to be more prevalent than previously thought and could have considerable effects on the populations of some species. This Perspective discusses the conservation issues raised by cancer in wildlife.
